.
MergerLinks Header Logo

Announced

Vertex to acquire Semma Therapeutics for $950m.

Financials

Edit Data
Transaction Value£785m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Acquisition

therapeutics

Pharmaceuticals

Friendly

medicine company

Private

diabetes medicines

Single Bidder

United States

Pending

Synopsis

Edit

Vetex Pharmaceuticals, a leading biotechnology firm to acquire Semma Therapeutics, a privately held biotechnology company pioneering the use of stem cell-derived human islets as a potentially curative treatment for type 1 diabetes, for $950m in cash. “Vertex has a proven track record of serial innovation and a deep commitment to developing transformative therapies for patients in need. Being a part of Vertex will allow the Semma team to rapidly and effectively advance our cell therapy and delivery approaches to patients who need them.” Bastiano Sanna, Semma President and CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US